Tokyo, Aug. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062605) titled 'Concordance analysis between HER2 immunohistochemistry and next generation sequencer in non-small lung cancer' on Aug. 19.
Study Type:
Observational
Primary Sponsor:
Institute - not applicable
Condition:
Condition - non-small lung cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To establish a HER2 screening system, we analysis HER2 overexpression by IHC in HER2 amplified NSCLC.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Recurrent or progressive non small lung cancer
18years of age or older at the time of obtaining informed consent for the study or at the time of opting out
Confirmed HER2 amplification status by Foundation One
Driver mutation is not required
Systematic chemotherapy history is not required
The specimens submitted to Foundation One are stored, and we can provide additional unstained slides as needed for IHC and FISH testing
Key exclusion criteria - Not applicable.
Target Size - 120
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 07 Month 30 Day
Anticipated trial start date - 2026 Year 09 Month 19 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071653
Disclaimer: Curated by HT Syndication.
